Clinical Trials: Study Operations & Enrollment

Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls

November 1, 2025

Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls Site Activation (US & UK): An Inspection-Ready Checklist of Documents, Timelines, and Pitfalls Outcome-first activation: open sites fast, safely, and in a way that survives FDA/MHRA scrutiny What “activation” must prove on day one Activation is not a flip of a calendar—it’s a verifiable condition set…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Feasibility Questions That Predict Enrollment (Scoring Sheet)

November 1, 2025

digi

Feasibility Questions That Predict Enrollment (Scoring Sheet) Feasibility Questions That Actually Predict Enrollment: A Defensible Scoring Sheet for US/UK/EU Programs Why feasibility must predict enrollment—not just describe the site—and how to make it inspection-ready From “profile of a site” to “probability of randomization” Traditional questionnaires catalog capabilities—beds, scanners, prior trials—but rarely answer the business-critical question:…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations

November 2, 2025

digi

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations Enrollment Funnel Analytics: How to Find the Leaks and Lift Randomizations with a System You Can Defend Why enrollment funnels decide study success—and how analytics turns “maybe” into predictable randomizations From activity to outcomes: measuring the right moments in the funnel Every clinical program lives or dies…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

US vs UK Recruitment Tactics That Actually Move Numbers

November 2, 2025

digi

US vs UK Recruitment Tactics That Actually Move Numbers US vs UK Recruitment Tactics That Actually Move Numbers (and Survive Inspection) Outcomes, not activity: the recruitment playbook that lifts randomizations on both sides of the Atlantic Why “more outreach” isn’t a strategy Recruitment fails when teams mistake volume for velocity. More emails, more postcards, more…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks

November 2, 2025

digi

Cut Delays: Prior Authorization, Imaging, Scheduling Bottlenecks Cut Delays Fast: How to Tame Prior Authorization, Imaging Queues, and Scheduling Bottlenecks Without Losing Compliance Why cycle-time kills enrollment—and the exact levers that buy back weeks in US/UK/EU programs The three hidden clocks that decide whether you randomize on time Across high-enrolling studies, cycle-time failures track back…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

NHS/NIHR Site Enablement: Capacity, Governance, Templates

November 3, 2025

digi

NHS/NIHR Site Enablement: Capacity, Governance, Templates NHS/NIHR Site Enablement: Building Capacity, Proving Governance, and Using Templates That Survive Inspection Why NHS/NIHR enablement decides UK enrollment velocity—and how to make it inspection-ready for US/UK/EU reviewers The enablement problem in one sentence Most UK programs stall not at feasibility, but between local confirmations and the first clinic…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Country Mix Optimization: Add Sites with Predictable Gains

November 3, 2025

digi

Country Mix Optimization: Add Sites with Predictable Gains Country Mix Optimization: How to Add Sites That Deliver Predictable Gains (Not Just More Complexity) Outcome-first site expansion: when adding countries lifts velocity—and when it only adds noise The real question: will a new country raise weekly randomizations with confidence? “Add more sites” is a reflex; “add…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Patient Materials That Convert: Plain-Language, Consent, Burden

November 3, 2025

digi

Patient Materials That Convert: Plain-Language, Consent, Burden Patient Materials That Convert: Turning Plain-Language Consent and Burden Transparency into Real Enrollment Why conversion-ready patient materials decide enrollment velocity—and how to make them inspection-proof Define “conversion” the regulator-friendly way Recruitment collateral isn’t successful because it’s beautiful; it’s successful when it predicts informed consent and sustained participation. In…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Investigator Meeting Content Map: Drive Screen Quality Day-1

November 3, 2025

digi

Investigator Meeting Content Map: Drive Screen Quality Day-1 Investigator Meeting Content Map to Drive Day-1 Screening Quality (and Keep It Inspection-Ready) What an Investigator Meeting must deliver: reproducible screen quality from the very first patient The outcome we’re buying with an IM The point of an Investigator Meeting (IM) is not inspiration—it is repeatable performance….

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships

November 4, 2025

digi

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships Rare-Disease Enrollment Playbook: Managing Windows, Building Support, and Structuring Partnerships That Actually Deliver Why rare-disease enrollment is different—and the operating model that makes it predictable What breaks in “business-as-usual” enrollment for rare conditions In rare diseases, enrollment fails for structural reasons: low prevalence spread across wide geographies, heterogeneous diagnostic…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment